罗氏有关负责人告诉经济观察报，玛巴洛沙韦的说明书长60厘 米，"目前罗氏在华药物中说明书尺寸最长为1米"。 作者：刘晓诺 封图：图虫创意 2025年12月中旬，小琪得了甲流。她在美团买了一盒罗氏的玛巴洛沙韦，花了200多元，拆开药 盒后，只看到两片药，但说明书比药还厚，像本小书。她感到"这药不简单"。 在流感季中，玛巴洛沙韦的超长说明书让许多患者印象深刻，有人吐槽："说明书展开之后大得像 被子，病好了说明书都没看完。" 不仅是流感药，有网民说，"奶奶拆开拜耳的利伐沙班片，看到里头（的说明书）像张报纸"。有 医生打开一盒抗肿瘤药，说明书铺满了一整张桌面。 2025年12月30日，罗氏有关负责人告诉经济观察报，玛巴洛沙韦的说明书长60厘米，"目前罗氏 在华药物中说明书尺寸最长为1米"，这款药物是法瑞西单抗，用于治疗眼科疾病。 2025年12月，一位网友的帖子 面对超长、字小且艰涩的说明书，一些患者深感困惑。 有患者说，说明书写的不良反应比病还重，干脆不吃药了。还有人质疑："能把说明书看懂了，我 都能当医生了。药厂是让患者学医的，还是服药治病的？" 对此，北京医院主任药师胡欣说："处方药说明书主要是给专业人士看的。 ...

Financial Performance - In Q3 2025, the company's revenue reached 719.55 million CNY, a year-on-year increase of 7.91% [3] - Net profit attributable to shareholders was 71.42 million CNY, up 123.90% compared to the same period last year [3] - For the first three quarters of 2025, total revenue was 2.29 billion CNY, reflecting an 18.36% growth year-on-year [3] - Net profit for the same period was 220.93 million CNY, a significant increase of 159.57% [3] Business Segments - Revenue growth in Q3 was primarily driven by the increase in formulation business, while raw materials and intermediates remained stable [3] - Non-sartan products continued to show stable growth, despite a slight decline in sartan products [3] Profitability Metrics - Overall gross margin for the first nine months of 2025 was 39.14%, an increase of 3.67 percentage points year-on-year [6] - Non-sartan raw material gross margin is on a steady upward trend due to commercialization of key products and cost optimization [6] - Sartan raw material gross margin remains stable despite competitive pricing pressures [6] Future Outlook - The formulation business is expected to enter a critical growth phase in 2026, with multiple products reaching significant sales volumes [4] - The company has set clear KPI targets for the formulation business, linking employee incentives directly to performance [4] R&D and Strategic Partnerships - R&D expenditures have been stable at around 1 billion CNY annually, with a focus on formulation development [8] - The company has established strategic partnerships with leading global pharmaceutical companies, enhancing its market position [8] - As of now, 78% of the company's raw material revenue comes from the regulated market, indicating a steady increase in scale and proportion [8]

Group 1 - Tianyu Co., Ltd. (SZ300702) has received preliminary approval for an environmental impact assessment for its subsidiary Binhai Sannong Pharmaceutical Chemical Co., Ltd.'s expansion and technical renovation project, which includes the production of various pharmaceutical products with a total investment of 85.55 million yuan [1] - The "A-share Green Report" project aims to enhance transparency in environmental information of listed companies, utilizing authoritative environmental regulatory data from 31 provinces and 337 cities [1] - The latest A-share Green Weekly Report indicated that four listed companies recently exposed environmental risks [1] Group 2 - Tianyu Co., Ltd.'s main business segments include generic drug raw materials and intermediates (72.18% of revenue), CDMO raw materials and intermediates (16.02%), formulations (11.43%), and others (0.37%) as of the 2025 semi-annual report [3] - The company's market capitalization is approximately 9.472 billion yuan, with reported revenues of 2.527 billion yuan for 2023, 2.631 billion yuan for 2024, and 1.567 billion yuan for the first half of 2025 [4] - The net profit attributable to the parent company is projected to be 273.593 million yuan for 2023, 559.351 million yuan for 2024, and 1.495118 billion yuan for the first half of 2025 [4]

Core Insights - The article highlights a significant increase in allergy testing and medication sales due to the seasonal rise in pollen allergies, particularly in cities like Beijing [1][4][5] Group 1: Allergy Trends - March marks the peak of pollen allergies in many regions, with Beijing experiencing particularly high pollen levels [1][3] - Data from China Weather Network indicates that pollen concentrations in cities like Beijing and Guangzhou are at "very high" levels, prompting warnings for individuals prone to allergies [1][4] Group 2: Medication Demand - There has been a notable surge in the demand for allergy medications, with a reported 330% increase in related drug searches in Beijing since mid-March [4] - Sales data from 1药网 shows a 48% month-on-month increase in allergy medication sales in Beijing [5] - Popular allergy medications include Reyonacort, Fluticasone, and other nasal sprays, with some products seeing over 50% year-on-year sales growth [4][5] Group 3: Clinical Insights - The number of patients presenting with pollen allergies has increased, with various symptoms ranging from allergic rhinitis to asthma [5][6] - Medical professionals recommend preventive measures and appropriate medication usage to manage seasonal allergies effectively [6][7] Group 4: Treatment Options - Treatment strategies include physical protection measures and pharmacological interventions, such as nasal corticosteroids and antihistamines [6][7] - Allergen-specific immunotherapy (AIT) is suggested for patients with severe symptoms, with an effectiveness rate of around 80% [8]